Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.
about
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based AnalysisA national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancerMusculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.Defining the level of evidence for technology adoption in the localized prostate cancer pathwayProstate-specific antigen screening in prostate cancer: perspectives on the evidenceImproving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.Can urinary PCA3 supplement PSA in the early detection of prostate cancer?Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer.Achieving optimal delivery of follow-up care for prostate cancer survivors: improving patient outcomesDevelopment and application of patient decision aidsGetting Black Men to Undergo Prostate Cancer Screening: The Role of Social CapitalProstate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.To screen or not to screen…: a comment on Lepore et Al.Utilization of prostate cancer screening according to dietary patterns and other demographic variables. The adventist health study-2.The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerEconomic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesIncidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide.Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men.The cost implications of prostate cancer screening in the Medicare population.Physician behaviors to promote informed decisions for prostate cancer screening: a National Research Network studyIdentification and function of proteolysis regulators in seminal fluid.Immunochromatographic diagnostic test analysis using Google Glass.Qualitative approach and treatment of patients with prostate cancer in cantonal hospital bihac during two years period.Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsyScreening for prostate cancer: an updated review.Rehabilitation of older cancer patients.A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.Prostate cancer: measuring PSA.Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection.Prostate-specific antigen-based prostate cancer screening: Past and future.Multigene panels in prostate cancer risk assessment: a systematic review.What's new in screening in 2015?Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond.Severe lack of comprehension of common prostate health terms among low-income inner-city men.Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men.Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.Role of miRNA let-7 and its major targets in prostate cancer.Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors.
P2860
Q26781093-5C7C267D-7E7A-4C4A-981F-1651E0D2BF02Q28652628-3C5EC060-28EB-474A-97E7-BD3A28BCDEEBQ33816511-73AE21AB-C74D-4A9B-906E-2AD137425074Q34061419-C7968B5C-3B84-4B5D-BB1E-B69E8794B4DBQ34354430-C9E44FB6-7540-4BC5-926F-27E22172061BQ34565363-E1F8EFFD-35A7-4E82-9D13-AF7AF61180ECQ34692263-34D9CC06-3EC6-4F5A-A1B5-D724060D87C1Q34918072-CEFF2C54-858C-4D5A-A38B-920AD9CEEAC0Q35040765-DB29BDBA-02AB-41EE-8535-7731AF2F8E33Q35212795-9E20789A-0C79-4D50-9FAD-1A5EE9EA4372Q35603765-7B6E1BDE-5D70-415F-B11E-848996F97865Q35756397-76340989-873D-4C97-9152-126596EB318DQ36226320-F563477D-7F35-4702-918B-2836D975B459Q36838478-3562C721-00E4-4D0E-A34F-D3674213FBB1Q36983384-547BD7D8-98F1-43F4-ADB2-D0BD676FE2DDQ37017011-E3DF37C0-0190-4821-9073-89B8483A28D4Q37095655-066BC031-23EC-4965-8697-AD6725408D8AQ37273869-F1FF4F9E-3BE4-460D-905F-F98EBDCCB6B7Q37315938-72954D65-6CF5-4663-93D0-B772D0B979F2Q37398384-E3BEC176-45F2-4FF0-99E5-0F4E0DDD40AFQ37402386-8063EEE3-D3F5-49FD-BFEE-2848EE9188DEQ37509388-7206A48F-AD52-435C-9C1C-2EA84E8B4C6DQ37581801-DD961893-FB7C-4F23-A107-D45DD9E7C2D4Q37705994-63732A79-B6BE-4878-BCBA-D13C0424B4BEQ37708662-23D58433-86F9-48E1-88EA-1C9A9AC9F4EFQ37710933-A3EF60FA-5774-4596-81FD-38294C312654Q38069188-0FABFBFF-6E86-4D71-AA72-613856F01BCEQ38074193-54695533-9A1E-4523-8801-4416F5155EB3Q38114143-4214FE3B-46FA-4C18-BD25-FA9AF5047B1FQ38210857-DFAAD15D-7BED-45AB-B294-DBEB91BC52E2Q38383052-857DFC20-61BA-44D8-88E2-DA2676D9567BQ38408501-FE634CCF-A81B-49E3-BD75-FFCF5531C7EBQ38596777-E3A71D58-7C19-4C69-BBCA-CCB83E268E7BQ38871819-1863D9FB-2FA0-48B9-893B-65618FE44F0FQ39141778-C05F1163-1980-4B3F-912E-CD9C2AD83DC5Q40115228-A117CB59-E7F1-4EB9-A9C2-25ABA19BD97AQ40392262-DB664E1F-7DCF-44D3-84A1-2F2743D4D85DQ40707371-7E1C851B-64A6-4AE8-B9F5-D31791F2C23AQ41890041-31916BAD-7935-494B-AA38-EED3BDEB0FDCQ41996680-9B8323A5-A015-4142-B6E9-B31926B6FC85
P2860
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Screening for prostate cancer ...... y Provisional Clinical Opinion
@nl
Screening for prostate cancer ...... Provisional Clinical Opinion.
@ast
Screening for prostate cancer ...... Provisional Clinical Opinion.
@de
Screening for prostate cancer ...... Provisional Clinical Opinion.
@en
type
label
Screening for prostate cancer ...... y Provisional Clinical Opinion
@nl
Screening for prostate cancer ...... Provisional Clinical Opinion.
@ast
Screening for prostate cancer ...... Provisional Clinical Opinion.
@de
Screening for prostate cancer ...... Provisional Clinical Opinion.
@en
prefLabel
Screening for prostate cancer ...... y Provisional Clinical Opinion
@nl
Screening for prostate cancer ...... Provisional Clinical Opinion.
@ast
Screening for prostate cancer ...... Provisional Clinical Opinion.
@de
Screening for prostate cancer ...... Provisional Clinical Opinion.
@en
P2093
P2860
P50
P3181
P356
P1476
Screening for prostate cancer ...... Provisional Clinical Opinion.
@en
P2093
Bruce Roth
D Andrew Loblaw
Howard Parnes
Ian Thompson
James Williams
Robert K Nam
Thomas K Oliver
P2860
P304
P3181
P356
10.1200/JCO.2012.43.3441
P407
P577
2012-07-16T00:00:00Z